Leerink Partnrs Brokers Increase Earnings Estimates for AMLX

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Amylyx Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($1.35) per share for the year, up from their prior estimate of ($1.75). The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals’ FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at ($1.00) EPS.

Other analysts have also issued reports about the stock. Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $3.00 to $11.00 in a research report on Monday, November 18th. Finally, Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research report on Friday, October 18th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Amylyx Pharmaceuticals Trading Up 4.0 %

Shares of AMLX opened at $3.65 on Friday. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $19.95. The firm’s 50-day moving average price is $4.18 and its 200-day moving average price is $3.60. The firm has a market capitalization of $250.20 million, a price-to-earnings ratio of -0.96 and a beta of -0.53.

Insider Activity

In related news, CEO Justin B. Klee sold 7,471 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the transaction, the chief executive officer now directly owns 3,176,788 shares in the company, valued at $12,834,223.52. The trade was a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its holdings in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after purchasing an additional 4,883 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after acquiring an additional 5,104 shares during the period. Algert Global LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $47,000. Hsbc Holdings PLC boosted its holdings in shares of Amylyx Pharmaceuticals by 57.9% during the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock valued at $150,000 after acquiring an additional 27,954 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $156,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.